Stents liberadores de sirolimus com e sem cobertura polimérica: análise seriada com angiografia e ultrassom intracoronariano tridimensional

Chamié, Daniel; Costa, J. Ribamar; Abizaid, Alexandre; Silva, José Fábio Almiro da; Feres, Fausto; Mattos, Luiz Alberto; Staico, Rodolfo; Costa, Ricardo; Siqueira, Dimytri; Tanajura, Luiz Fernando; Sousa, Amanda G. M. R.; Sousa, J. Eduardo

doi:10.1590/s2179-83972009000100007

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The report of Chamié et al 9 is the latest study to emerge from a research group that has been prominently involved in DES innovation since the inception of this technology. The VESTAsync stent described by the investigators is a notable addition to next generation DES devices.…”

Section: See Related Articlementioning

confidence: 99%

“…In terms of comparison versus Cypher, the VESTAsync is associated with a lesser extent of neointimal hyperplasia suppression at both 4 and 12 months (though for reasons of small sample size the findings are not statistically significant). This is most likely related to less favorable sirolimus release-kinetics over the first 10 days (see Figure 4 of Chamié et al 9 ). Although the VESTAsync stent takes longer to discharge 80% of its drug-load (60 days as compared to 30 days with Cypher), half of the drug is released within the first 10 days.…”

Section: See Related Articlementioning

confidence: 99%

See 1 more Smart Citation

Stents farmacológicos sem polímero: um InVEST(A)imento para o futuro?

Byrne

Kastrati

2009

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Section: See Related Articlementioning

confidence: 99%

Section: See Related Articlementioning

confidence: 99%

Stents farmacológicos sem polímero: um InVEST(A)imento para o futuro?

Byrne

Kastrati

2009

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

“…[5][6][7][8] Vascular healing in response to DES implantation is dynamic and depends on the type of drug used, which in turn depends on its release kinetics from durable or biodegradable polymers. [9][10][11][12][13][14][15][16] Evaluation through histology does not allow for time-dependent analyses, and there are additional limitations, such as tissue loss related to the technique employed for material preparation (non-satisfactory cutting or colouring, thickness, and angle of the cut).…”

mentioning

confidence: 99%

Evolução temporal da proliferação neointimal após implante de dois tipos de stent farmacológico com polímeros biodegradáveis em modelo porcino: avaliação qualitativa por tomografia de coerência óptica sequencial

Galon¹,

Takimura²,

Carvalho³

et al. 2012

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Background: Based on the hypothesis that the neointima found in drug-eluting stents (DES) with biodegradable polymers at 28 days is not a definitive neointima and that optical coherence tomography (OCT) is an effective method for sequential neointimal evaluation, we aim, in this experimental study, to compare OCT findings at 28 and 90 days, in two different DES with biodegradable polymers: the sirolimus-eluting stent (Inspiron ® , Scitech) and the biolimus A9-eluting stent (Biomatrix ® , Biosensors International). Methods: Overall, 6 non-atherosclerotic pigs were submitted to the implantation of 6 Inspiron ® stents and 6 Biomatrix ® stents. Each pig received both stent types, one in each coronary artery (left anterior descending artery and circumflex artery) and after 28 and 90 days qualitative in-stent OCT analyses were performed at 1-millimeter intervals. results: Qualitative assessment was performed in-stent pairing millimeter by millimeter. Heterogeneous neointimal tissue was evidenced in 39% at 28 days and in 0% at 90 days, the presence of intraluminal tissue in 18% at 28 days and in 0% at 90 days, luminal irregularity in 62% at 28 days and in 2% at 90 days (P < 0.005). There was no difference between groups regarding the quality of the neointima over time (P > 0.05). Conclusions: The OCT findings corroborate the hypothesis that the neointima found in DES with biode-

show abstract

“…Vários outros stents farmacológicos estão sob avaliação experimental e clínica e alguns deles estão liberados para uso clínico na Europa, na Ásia e no Brasil. Alguns desses stents são constituídos de novas ligas metálicas como platina-cromo 6 , não são recobertos por polímero 7,8 ou são bioabsorvíveis 9 (estes últimos considerados stents de terceira geração). O stent BioMatrix TM (Biosensors International, Cingapura) é um stent de aço inoxidável inspirado no S-Stent TM (Biosensors International), recoberto com polímero biodegradável (PLA), exclusivamente em sua face abluminal, e que libera biolimus A9.…”

unclassified